Sanjay Basu talks with The Lancet Diabetes & Endocrinology about what is an affordable price for newer type 2 diabetes medicines in low-income and middle-incomes countries.
Read the full article:
https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00240-0/fulltext